Phathom begins Phase 3 pHalcon-NERD-302 trial of VOQUEZNA as-needed in NERD, topline due Q1 2028

Phathom initiated patient screening for a registrational Phase 3 study of VOQUEZNA as-needed in Non—Erosive GERD, with topline results expected in Q1 2028.Key Highlights:Original SEC Filing: Phathom Pharmaceuticals, Inc. [ PHAT ] - 8-K - Sep. 29, 2026This is an AI-powered summary. It may contain in…